Can we prevent Parkinson’s disease with n-3 polyunsaturated fatty acids?

It is increasingly clear that nongenetic elements play a crucial role in the pathogenesis of Parkinson’s disease (PD), yet no modifiable environmental risk factor has been clearly identified. Recent work in animal models of PD supports the contention that n-3 polyunsaturated fatty acids (PUFA) found in fatty fish are neuroprotective in PD. Moreover, a few epidemiological reports suggest that a high intake of fish (and n-3 PUFA) is associated with a lower risk of developing PD. The question remains whether docosahexenoic or eicosapentenoic acid is the brain n-3 PUFA responsible for the observed neuroprotective effect. Despite these encouraging data, the development of n-3 PUFA as drugs is hindered by the fact that they are nonpatentable compounds, at least in their natural form. Nevertheless, owing to their favorable safety profile, it should be a high priority to pursue preclinical and clinical studies on the nutraceutical properties of n-3 PUFA in PD.

[1]  F. Cicchetti,et al.  Beneficial effects of dietary omega‐3 polyunsaturated fatty acid on toxin‐induced neuronal degeneration in an animal model of Parkinson's disease , 2008, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[2]  R. Weisinger,et al.  The role of omega-3 fatty acids in mood disorders. , 2008, Current opinion in investigational drugs.

[3]  N. Salem,et al.  Whole body distribution of deuterated linoleic and alpha-linolenic acids and their metabolites in the rat. , 2007, Journal of lipid research.

[4]  N. Brot,et al.  Methionine Sulfoxide Reductase A and a Dietary Supplement S-Methyl-L-Cysteine Prevent Parkinson's-Like Symptoms , 2007, The Journal of Neuroscience.

[5]  Gang Hu,et al.  Coffee and tea consumption and the risk of Parkinson's disease , 2007, Movement disorders : official journal of the Movement Disorder Society.

[6]  Xiang Gao,et al.  Prospective study of dietary pattern and risk of Parkinson disease. , 2007, The American journal of clinical nutrition.

[7]  S. Rapoport,et al.  Brain metabolism of nutritionally essential polyunsaturated fatty acids depends on both the diet and the liver. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[8]  P. Mukherjee,et al.  Docosanoids are multifunctional regulators of neural cell integrity and fate: significance in aging and disease. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[9]  G. Cole,et al.  Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: evidence from animal studies. , 2007, Prostaglandins, leukotrienes, and essential fatty acids.

[10]  D. Dexter,et al.  Short-Term Supplementation with Plant Extracts Rich in Flavonoids Protect Nigrostriatal Dopaminergic Neurons in a Rat Model of Parkinson's Disease , 2007, Journal of the American College of Nutrition.

[11]  Hee-Yong Kim Novel Metabolism of Docosahexaenoic Acid in Neural Cells* , 2007, Journal of Biological Chemistry.

[12]  J. Andersen,et al.  Iron and Paraquat as Synergistic Environmental Risk Factors in Sporadic Parkinson's Disease Accelerate Age-Related Neurodegeneration , 2007, The Journal of Neuroscience.

[13]  Dana Kilroy,et al.  Eicosapentaenoic acid confers neuroprotection in the amyloid-β challenged aged hippocampus , 2007, Neurobiology of Aging.

[14]  Michael J Thun,et al.  Consumption of dairy products and risk of Parkinson's disease. , 2007, American journal of epidemiology.

[15]  S. Rapoport,et al.  Docosahexaenoic acid synthesis from alpha-linolenic acid by rat brain is unaffected by dietary n-3 PUFA deprivation. , 2007, Journal of lipid research.

[16]  Frank M LaFerla,et al.  Dietary Docosahexaenoic Acid and Docosapentaenoic Acid Ameliorate Amyloid-β and Tau Pathology via a Mechanism Involving Presenilin 1 Levels , 2007, The Journal of Neuroscience.

[17]  S. Przedborski,et al.  Protocol for the MPTP mouse model of Parkinson's disease , 2007, Nature Protocols.

[18]  J. Duarte,et al.  Paraquat exposure as an etiological factor of Parkinson's disease. , 2006, Neurotoxicology.

[19]  E. Bézard A call for clinically driven experimental design in assessing neuroprotection in experimental Parkinsonism. , 2006, Behavioural pharmacology.

[20]  H. Tanila,et al.  Impact of different saturated fatty acid, polyunsaturated fatty acid and cholesterol containing diets on beta-amyloid accumulation in APP/PS1 transgenic mice , 2006, Neurobiology of Disease.

[21]  M. Thun,et al.  Pesticide exposure and risk for Parkinson's disease , 2006, Annals of neurology.

[22]  A Hofman,et al.  Dietary folate, vitamin B12, and vitamin B6 and the risk of Parkinson disease , 2006, Neurology.

[23]  M. Tremblay,et al.  Neuroprotective effects of cystamine in aged parkinsonian mice , 2006, Neurobiology of Aging.

[24]  F. Dick,et al.  Parkinson's disease and pesticide exposures. , 2006, British medical bulletin.

[25]  A. Rajput,et al.  Postmortem brain fatty acid profile of levodopa-treated Parkinson disease patients and parkinsonian monkeys , 2006, Neurochemistry International.

[26]  M. Farrer Genetics of Parkinson disease: paradigm shifts and future prospects , 2006, Nature Reviews Genetics.

[27]  F. Calon Nonpatentable drugs and the cost of our ignorance , 2006, Canadian Medical Association Journal.

[28]  A. Brice Genetics of Parkinson's disease: LRRK2 on the rise. , 2005, Brain : a journal of neurology.

[29]  R. Gross,et al.  Systemic exposure to paraquat and maneb models early Parkinson's disease in young adult rats , 2005, Neurobiology of Disease.

[30]  Takashi Morihara,et al.  Dietary n‐3 polyunsaturated fatty acid depletion activates caspases and decreases NMDA receptors in the brain of a transgenic mouse model of Alzheimer's disease , 2005, The European journal of neuroscience.

[31]  Andrew B West,et al.  Molecular pathophysiology of Parkinson's disease. , 2005, Annual review of neuroscience.

[32]  P. J. Koudstaal,et al.  Dietary fatty acids and the risk of Parkinson disease , 2005, Neurology.

[33]  Philip J. Landrigan,et al.  Early Environmental Origins of Neurodegenerative Disease in Later Life , 2005, Environmental health perspectives.

[34]  J. Jankovic,et al.  Neuroprotective therapy in Parkinson's disease and motor complications: A search for a pathogenesis‐targeted, disease‐modifying strategy , 2005, Movement disorders : official journal of the Movement Disorder Society.

[35]  N. Bazan Neuroprotectin D1 (NPD1): A DHA‐Derived Mediator that Protects Brain and Retina Against Cell Injury‐Induced Oxidative Stress , 2005, Brain pathology.

[36]  J. Fessel,et al.  The Biochemistry of the Isoprostane, Neuroprostane, and Isofuran Pathways of Lipid Peroxidation , 2005, Chemistry and physics of lipids.

[37]  Takashi Morihara,et al.  A Diet Enriched with the Omega-3 Fatty Acid Docosahexaenoic Acid Reduces Amyloid Burden in an Aged Alzheimer Mouse Model , 2005, The Journal of Neuroscience.

[38]  J. Bell,et al.  Half‐lives of docosahexaenoic acid in rat brain phospholipids are prolonged by 15 weeks of nutritional deprivation of n‐3 polyunsaturated fatty acids , 2004, Journal of neurochemistry.

[39]  M. Feany,et al.  New genetic insights into Parkinson's disease. , 2004, The New England journal of medicine.

[40]  M. Lavialle,et al.  Polyunsaturated fatty acids in the central nervous system: evolution of concepts and nutritional implications throughout life. , 2004, Reproduction, nutrition, development.

[41]  Takashi Morihara,et al.  Docosahexaenoic Acid Protects from Dendritic Pathology in an Alzheimer's Disease Mouse Model , 2004, Neuron.

[42]  A. Schapira Disease modification in Parkinson's disease , 2004, The Lancet Neurology.

[43]  S. Rapoport,et al.  In vivo approaches to quantifying and imaging brain arachidonic and docosahexaenoic acid metabolism. , 2003, The Journal of pediatrics.

[44]  Cecil M. Burchfiel,et al.  Environmental, life-style, and physical precursors of clinical Parkinson’s disease: recent findings from the Honolulu-Asia Aging Study , 2003, Journal of Neurology.

[45]  W. Dauer,et al.  Parkinson's Disease Mechanisms and Models , 2003, Neuron.

[46]  Miguel A Hernán,et al.  Dietary intakes of fat and risk of Parkinson's disease. , 2003, American journal of epidemiology.

[47]  R. Albin,et al.  Neuroprotective agents for clinical trials in Parkinson’s disease , 2003, Neurology.

[48]  A. Manning-Boğ,et al.  Environmental factors in Parkinson's disease. , 2002, Neurotoxicology.

[49]  Ted M. Dawson,et al.  Animal Models of PD Pieces of the Same Puzzle? , 2002, Neuron.

[50]  Y. Ishibashi,et al.  Docosahexaenoic acid provides protection from impairment of learning ability in Alzheimer's disease model rats , 2002, Journal of neurochemistry.

[51]  T. Sherer,et al.  Animal models of Parkinson's disease. , 2002, BioEssays : news and reviews in molecular, cellular and developmental biology.

[52]  D. Jump The Biochemistry of n-3 Polyunsaturated Fatty Acids* 210 , 2002, The Journal of Biological Chemistry.

[53]  Hee-Yong Kim,et al.  Mechanisms of action of docosahexaenoic acid in the nervous system , 2001, Lipids.

[54]  M. Beal,et al.  Experimental models of Parkinson's disease , 2001, Nature Reviews Neuroscience.

[55]  C. C. Johnson,et al.  Adult nutrient intake as a risk factor for Parkinson's disease. , 1999, International journal of epidemiology.

[56]  J W Langston,et al.  Parkinson disease in twins: an etiologic study. , 1999, JAMA.

[57]  H Checkoway,et al.  Dietary factors in Parkinson's disease: The role of food groups and specific foods , 1999, Movement disorders : official journal of the Movement Disorder Society.

[58]  G. Nisticó,et al.  Paraquat: a useful tool for the in vivo study of mechanisms of neuronal cell death. , 1998, Pharmacology & toxicology.

[59]  E. Anggard,et al.  Evidence for the formation of F3-isoprostanes during peroxidation of eicosapentaenoic acid. , 1997, Biochemical and biophysical research communications.

[60]  A. Seidler,et al.  Diet and Parkinson's disease , 1997, Neurology.

[61]  M. Lagarde,et al.  Retroconversion and metabolism of [13C]22:6n-3 in humans and rats after intake of a single dose of [13C]22:6n-3-triacylglycerols. , 1996, The American journal of clinical nutrition.

[62]  A. Seidler,et al.  Diet and Parkinson's disease I , 1996, Neurology.

[63]  D. Morens,et al.  Case‐control study of idiopathic Parkinson's disease and dietary vitamin E intake , 1996, Neurology.

[64]  Karen Marder,et al.  Dietary lipids and antioxidants in Parkinson's disease: A population‐based, case‐control study , 1996, Annals of neurology.

[65]  V. Hachinski,et al.  Environmental Exposures in Elderly Canadians With Parkinson’s Disease , 1995, Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques.

[66]  T. Hagve,et al.  Peroxisomal retroconversion of docosahexaenoic acid (22:6(n-3)) to eicosapentaenoic acid (20:5(n-3)) studied in isolated rat liver cells. , 1991, Biochimica et biophysica acta.

[67]  E. Hirsch,et al.  How to judge animal models of Parkinson's disease in terms of neuroprotection. , 2006, Journal of neural transmission. Supplementum.

[68]  Thomas Gasser,et al.  Genetics of Parkinson's disease , 2005, Current opinion in neurology.

[69]  P. Jenner,et al.  Oxidative stress in Parkinson's disease , 2003, Annals of neurology.

[70]  S. Hunot,et al.  Neuroinflammatory processes in Parkinson's disease , 2003, Annals of neurology.

[71]  K. Marder,et al.  Dietary iron, animal fats, and risk of Parkinson's disease. , 1998, Movement disorders : official journal of the Movement Disorder Society.